Skip to content
Search

Latest Stories

Online pharmacy PillTime installs Titan PMR in its new state-of-art facility to boost prescription growth

Online pharmacy PillTime has taken a step to boost its prescription growth by implementing new Patient Medication Record (PMR) system Titan in its state-of-the-art premises.

PillTime moved to new, expanded 26,000sqft premises in Cribbs Causeway on the edge of Bristol earlier this year, where it has also installed state-of-the-art robotics in a bid to significantly enhance future productivity and capacity.


Teething problems over Easter weekend saw PillTime struggling to seamlessly integrate all the new systems and processes while physically moving premises which affected service delivery and customer support.

However, CEO Leighton Humphreys was supported by Tariq Muhammad, CEO of Invatech Health, who is a former community pharmacist and has worked with independent pharmacies around the UK as well as larger online businesses, to integrate Titan into their workflows.

Alongside integration work, Muhammad and his team supported PillTime with necessary design, governance and pharmacy expertise as the company struggled to meet its usual high standards for dispensing medicines to patients.

“We had ambitious plans for our move but things turned out to be more complicated than we had envisaged,” said Humphreys. “So we are extremely grateful to Tariq and his team of pharmacists for the support they provided.

“We thank our customers for sticking with us during this challenging period for our business and we’re looking ahead now. Titan will make a major difference to how we operate and grow, alongside the cutting-edge robotics and innovative pouching system which are unique at this scale.”

Founded in 2016, PillTime currently provides prescription medicines in daily dosage pouches to around 11,000 NHS patients across the UK.

Following the deployment of Titan, it forecasts 900 per cent growth in the next two to three years. It hopes to hit the 100,000 patient mark by the end of 2023 – a figure it says is still ‘only a drop in the ocean’.

Last year Invatech Health announced a further £950,000 loan from Innovate UK, under a programme to support game-changing innovations in the UK’s SME community.

Muhammad, said he was pleased to support PillTime.

“Having established our systems in the community pharmacy sector, we are now enjoying rolling out Titan Enterprise to innovative online pharmacy businesses,” he said, adding: “We’re helping them process prescriptions safely at a speed which is unheard of until now.

“Of course It’s great to be collaborating with another innovative Bristol-based business which is looking to help transform the way that people manage and access their medication.

“Now all systems are fully operational, we are excited to see how PillTime develops over the coming months and years.”

Humphreys said that PillTime’s offering of medication in easy-to-understand pouches provided a solution to several problems, from reducing the requirement for carers and nursing homes, while minimising hospital admissions through medication errors.

“There are far too many instances of medications being properly dispensed but incorrectly taken, leading to people not getting better as they should do,” he said.

“In some parts of the world the pouching system has become standard because it’s foolproof, as long as the patient is fully aware. We want that to happen here, too. Our mission is cost savings to the NHS and a better quality of convenience and level of healthcare. “

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less